The Nature of Myeloid-Derived Suppressor Cells in the Tumor Microenvironment

Trends in Immunology

Volumn 37, Issue 3, 2016, Pages 208-220

  Kumar, Vinit ^a   Patel, Sima ^a   Tcyganov, Evgenii ^a   Gabrilovich, Dmitry I ^a  

^a WISTAR INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BONE MARROW CELL; CELL DIFFERENTIATION; CELL FATE; CELL MATURATION; CELLULAR DISTRIBUTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LYMPHOID ORGAN; MYELOID DERIVED SUPPRESSOR CELL; NONHUMAN; REGULATORY MECHANISM; REVIEW; SUPPRESSOR CELL; TUMOR GROWTH; TUMOR MICROENVIRONMENT; ANIMAL; CARCINOGENESIS; IMMUNOLOGY; MACROPHAGE; METABOLISM; MYELOID-DERIVED SUPPRESSOR CELL; NEOPLASM; PHYSIOLOGY;

CHEMOKINE;

ANIMALS; CARCINOGENESIS; CELL DIFFERENTIATION; CHEMOKINES; HUMANS; IMMUNOSUPPRESSION; MACROPHAGES; MYELOID-DERIVED SUPPRESSOR CELLS; NEOPLASMS; TUMOR MICROENVIRONMENT;

EID: 84959542771     PISSN: 14714906     EISSN: 14714981     Source Type: Journal    
DOI: 10.1016/j.it.2016.01.004     Document Type: Review

References (111)

1. Condamine T., et al. Regulation of tumor metastasis by myeloid-derived suppressor cells. Annu. Rev. Med. 2015, 66:97-110.
2. Talmadge J.E., Gabrilovich D.I. History of myeloid-derived suppressor cells. Nat. Rev. Cancer 2013, 13:739-752.
3. Marvel D., Gabrilovich D.I. Myeloid-derived suppressor cells in the tumor microenvironment: expect the unexpected. J. Clin. Invest. 2015, 125:3356-3364.
4. Ugel S., et al. Tumor-induced myeloid deviation: when myeloid-derived suppressor cells meet tumor-associated macrophages. J. Clin. Invest. 2015, 125:3365-3376.
5. Kumar V., et al. CD45 phosphatase inhibits STAT3 transcription factor activity in myeloid cells and promotes tumor associated macrophage differentiation. Immunity 2016, (in press).
6. Condamine T., et al. Transcriptional regulation of myeloid-derived suppressor cells. J. Leukoc. Biol. 2015, 98:913-922.
7. Porembka M.R., et al. Pancreatic adenocarcinoma induces bone marrow mobilization of myeloid-derived suppressor cells which promote primary tumor growth. Cancer Immunol. Immunother. 2012, 61:1373-1385.
8. Capietto A.H., et al. Down-regulation of PLCgamma2-beta-catenin pathway promotes activation and expansion of myeloid-derived suppressor cells in cancer. J. Exp. Med. 2013, 210:2257-2271.
9. Sinha P., et al. Proinflammatory s100 proteins regulate the accumulation of myeloid-derived suppressor cells. J. Immunol. 2008, 181:4666-4675.
10. Youn J.I., et al. Characterization of the nature of granulocytic myeloid-derived suppressor cells in tumor-bearing mice. J. Leukoc. Biol. 2012, 91:167-181.
11. Corzo C.A., et al. Mechanism regulating reactive oxygen species in tumor-induced myeloid-derived suppressor cells. J. Immunol. 2009, 182:5693-5701.
12. Nagaraj S., et al. Altered recognition of antigen is a mechanism of CD8+ T cell tolerance in cancer. Nat. Med. 2007, 13:828-835.
13. Highfill S.L., et al. Bone marrow myeloid-derived suppressor cells (MDSCs) inhibit graft-versus-host disease (GVHD) via an arginase-1-dependent mechanism that is up-regulated by interleukin-13. Blood 2010, 116:5738-5747.
14. Arina A., Bronte V. Myeloid-derived suppressor cell impact on endogenous and adoptively transferred T cells. Curr. Opin. Immunol. 2015, 33:120-125.
15. Marigo I., et al. Tumor-induced tolerance and immune suppression depend on the C/EBP? transcription factor. Immunity 2010, 32:790-802.
16. Chalmin F., et al. Membrane-associated Hsp72 from tumor-derived exosomes mediates STAT3-dependent immunosuppressive function of mouse and human myeloid-derived suppressor cells. J. Clin. Invest. 2010, 120:457-471.
17. Nefedova Y., et al. Hyperactivation of STAT3 is involved in abnormal differentiation of dendritic cells in cancer. J. Immunol. 2004, 172:464-474.
18. Waight J.D., et al. Myeloid-derived suppressor cell development is regulated by a STAT/IRF-8 axis. J. Clin. Invest. 2013, 123:4464-4478.
19. Cheng P., et al. Inhibition of dendritic cell differentiation and accumulation of myeloid-derived suppressor cells in cancer is regulated by S100A9 protein. J. Exp. Med. 2008, 205:2235-2249.
20. Sonda N., et al. miR-142-3p prevents macrophage differentiation during cancer-induced myelopoiesis. Immunity 2013, 38:1236-1249.
21. Gabrilovich D.I., et al. Coordinated regulation of myeloid cells by tumours. Nat. Rev. Immunol. 2012, 12:253-268.
22. Ueha S., et al. Myeloid cell population dynamics in healthy and tumor-bearing mice. Int. Immunopharmacol. 2011, 11:783-788.
23. Damuzzo V., et al. Complexity and challenges in defining myeloid-derived suppressor cells. Cytometry Part B Clin. Cytom. 2015, 88:77-91.
24. Wang G., et al. Targeting YAP-dependent MDSC infiltration impairs tumor progression. Cancer Discov. 2016, 6:80-95.
25. Chun E., et al. CCL2 promotes colorectal carcinogenesis by enhancing polymorphonuclear myeloid-derived suppressor cell population and function. Cell Rep. 2015, 12:244-257.
26. Raychaudhuri B., et al. Myeloid derived suppressor cell infiltration of murine and human gliomas is associated with reduction of tumor infiltrating lymphocytes. J. Neurooncol. 2015, 122:293-301.
27. Eruslanov E., et al. Circulating and tumor-infiltrating myeloid cell subsets in patients with bladder cancer. Int. J. Cancer 2012, 130:1109-1119.
28. Yu J., et al. Myeloid-derived suppressor cells suppress antitumor immune responses through IDO expression and correlate with lymph node metastasis in patients with breast cancer. J. Immunol. 2013, 190:3783-3797.
29. Kitamura T., et al. CCL2-induced chemokine cascade promotes breast cancer metastasis by enhancing retention of metastasis-associated macrophages. J. Exp. Med. 2015, 212:1043-1059.
30. Murdoch C., et al. Mechanisms regulating the recruitment of macrophages into hypoxic areas of tumors and other ischemic tissues. Blood 2004, 104:2224-2234.
31. Qian B.Z., et al. CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis. Nature 2011, 475:222-225.
32. Huang B., et al. CCL2/CCR2 pathway mediates recruitment of myeloid suppressor cells to cancers. Cancer Lett. 2007, 252:86-92.
33. Inamoto S., et al. Loss of SMAD4 promotes colorectal cancer progression by accumulation of myeloid-derived suppressor cells through CCL15-CCR1 chemokine axis. Clin. Cancer Res. 2016, 2:492.
34. Allavena P., et al. The inflammatory micro-environment in tumor progression: the role of tumor-associated macrophages. Crit. Rev. Oncol. Hematol. 2008, 66:1-9.
35. Sica A., et al. defective expression of the monocyte chemotactic protein-1 receptor CCR2 in Macrophages associated with human ovarian carcinoma. J. Immunol. 2000, 164:733-738.
36. Reichel C.A., et al. C-C motif chemokine CCL3 and canonical neutrophil attractants promote neutrophil extravasation through common and distinct mechanisms. Blood 2012, 120:880-890.
37. Florey O., Haskard D.O. Sphingosine 1-phosphate enhances Fc gamma receptor-mediated neutrophil activation and recruitment under flow conditions. J. Immunol. 2009, 183:2330-2336.
38. Sceneay J., et al. Primary tumor hypoxia recruits CD11b+/Ly6Cmed/Ly6G+ immune suppressor cells and compromises NK cell cytotoxicity in the premetastatic niche. Cancer Res. 2012, 72:3906-3911.
39. Seubert B., et al. Tissue inhibitor of metalloproteinases (TIMP)-1 creates a premetastatic niche in the liver through SDF-1/CXCR4-dependent neutrophil recruitment in mice. Hepatology 2015, 61:238-248.
40. Huh S.J., et al. Transiently entrapped circulating tumor cells interact with neutrophils to facilitate lung metastasis development. Cancer Res. 2010, 70:6071-6082.
41. Ichikawa M., et al. S100A8/A9 activate key genes and pathways in colon tumor progression. Mol. Cancer Res. 2011, 9:133-148.
42. Kowanetz M., et al. Granulocyte-colony stimulating factor promotes lung metastasis through mobilization of Ly6G+Ly6C+ granulocytes. Proc. Natl. Acad. Sci. U.S.A. 2010, 107:21248-21255.
43. Quatromoni J.G., et al. An optimized disaggregation method for human lung tumors that preserves the phenotype and function of the immune cells. J. Leukoc. Biol. 2015, 97:201-209.
44. Raber P.L., et al. Subpopulations of myeloid-derived suppressor cells impair T cell responses through independent nitric oxide-related pathways. Int. J. Cancer 2014, 134:2853-2864.
45. Raber P., et al. Metabolism of L-arginine by myeloid-derived suppressor cells in cancer: mechanisms of T cell suppression and therapeutic perspectives. Immunol. Invest. 2012, 41:614-634.
46. Srivastava M.K., et al. Myeloid-derived suppressor cells inhibit T-cell activation by depleting cystine and cysteine. Cancer Res. 2010, 70:68-77.
47. Molon B., et al. Chemokine nitration prevents intratumoral infiltration of antigen-specific T cells. J. Exp. Med. 2011, 208:1949-1962.
48. Ostrand-Rosenberg S., Sinha P. Myeloid-derived suppressor cells: linking inflammation and cancer. J. Immunol. 2009, 182:4499-4506.
49. Pan P.Y., et al. Immune stimulatory receptor CD40 is required for T-cell suppression and T regulatory cell activation mediated by myeloid-derived suppressor cells in cancer. Cancer Res. 2010, 70:99-108.
50. Mao Y., et al. Inhibition of tumor-derived prostaglandin-e2 blocks the induction of myeloid-derived suppressor cells and recovers natural killer cell activity. Clin. Cancer Res. 2014, 20:4096-4106.
51. Youn J.I., et al. Epigenetic silencing of retinoblastoma gene regulates pathologic differentiation of myeloid cells in cancer. Nat. Immunol. 2013, 14:211-220.
52. Messmer M.N., et al. Tumor-induced myeloid dysfunction and its implications for cancer immunotherapy. Cancer Immunol. Immunother. 2015, 64:1-13.
53. Solito S., et al. Myeloid-derived suppressor cell heterogeneity in human cancers. Ann. NY. Acad. Sci. 2014, 1319:47-65.
54. Nagaraj S., et al. Mechanism of T cell tolerance induced by myeloid-derived suppressor cells. J. Immunol. 2010, 184:3106-3116.
55. Cuenca A.G., et al. A paradoxical role for myeloid-derived suppressor cells in sepsis and trauma. Mol. Med. 2011, 17:281-292.
56. Dolcetti L., et al. Hierarchy of immunosuppressive strength among myeloid-derived suppressor cell subsets is determined by GM-CSF. Eur. J. Immunol. 2010, 40:22-35.
57. Haverkamp J.M., et al. Myeloid-derived suppressor activity is mediated by monocytic lineages maintained by continuous inhibition of extrinsic and intrinsic death pathways. Immunity 2014, 41:947-959.
58. Hossain F., et al. Inhibition of fatty acid oxidation modulates immunosuppressive functions of myeloid-derived suppressor cells and enhances cancer therapies. Cancer Immunol. Res. 2015, 3:1236-1247.
59. Maenhout S.K., et al. Enhanced suppressive capacity of tumor-infiltrating myeloid-derived suppressor cells compared with their peripheral counterparts. Int. J. Cancer 2014, 134:1077-1090.
60. Haverkamp J.M., et al. In vivo suppressive function of myeloid-derived suppressor cells is limited to the inflammatory site. Eur. J. Immunol. 2011, 41:749-759.
61. Corzo C.A., et al. HIF-1alpha regulates function and differentiation of myeloid-derived suppressor cells in the tumor microenvironment. J. Exp. Med. 2010, 207:2439-2453.
62. Mairhofer D.G., et al. Impaired gp100-specific CD8(+) T-cell responses in the presence of myeloid-derived suppressor cells in a spontaneous mouse melanoma model. J. Invest. Dermatol. 2015, 135:2785-2793.
63. Cimen Bozkus C., et al. Expression of cationic amino acid transporter 2 is required for myeloid-derived suppressor cell-mediated control of T cell immunity. J. Immunol. 2015, 195:5237-5250.
64. Schlecker E., et al. Tumor-infiltrating monocytic myeloid-derived suppressor cells mediate CCR5-dependent recruitment of regulatory T cells favoring tumor growth. J. Immunol. 2012, 189:5602-5611.
65. Noman M.Z., et al. PD-L1 is a novel direct target of HIF-1alpha, and its blockade under hypoxia enhanced MDSC-mediated T cell activation. J. Exp. Med. 2014, 211:781-790.
66. Ridder K., et al. Extracellular vesicle-mediated transfer of functional RNA in the tumor microenvironment. Oncoimmunology 2015, 4:e1008371.
67. Liu C.Y., et al. Population alterations of L-arginase- and inducible nitric oxide synthase-expressed CD11b+/CD14(-)/CD15+/CD33+ myeloid-derived suppressor cells and CD8+ T lymphocytes in patients with advanced-stage non-small cell lung cancer. J. Cancer Res. Clin. Oncol. 2010, 136:35-45.
68. Gabrilovich D.I., Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat. Rev. Immunol. 2009, 9:162-174.
69. Yona S., et al. Fate mapping reveals origins and dynamics of monocytes and tissue macrophages under homeostasis. Immunity 2013, 38:79-91.
70. Schulz C., et al. A lineage of myeloid cells independent of Myb and hematopoietic stem cells. Science 2012, 336:86-90.
71. Sheng J., et al. Most tissue-resident macrophages except microglia are derived from fetal hematopoietic stem cells. Immunity 2015, 43:382-393.
72. Franklin R.A., et al. The cellular and molecular origin of tumor-associated macrophages. Science 2014, 344:921-925.
73. Movahedi K., et al. Different tumor microenvironments contain functionally distinct subsets of macrophages derived from Ly6C(high) monocytes. Cancer Res. 2010, 70:5728-5739.
74. Mazzieri R., et al. Targeting the ANG2/TIE2 axis inhibits tumor growth and metastasis by impairing angiogenesis and disabling rebounds of proangiogenic myeloid cells. Cancer Cell 2011, 19:512-526.
75. Biswas S.K., et al. Tumor-associated macrophages: functional diversity, clinical significance, and open questions. Semin. Immunopathol. 2013, 35:585-600.
76. Cortez-Retamozo V., et al. Origins of tumor-associated macrophages and neutrophils. Proc. Natl. Acad. Sci. U.S.A. 2012, 109:2491-2496.
77. Lee M., et al. Resiquimod, a TLR7/8 agonist, promotes differentiation of myeloid-derived suppressor cells into macrophages and dendritic cells. Arch. Pharm. Res. 2014, 37:1234-1240.
78. Zhang T., et al. Thrombin facilitates invasion of ovarian cancer along peritoneum by inducing monocyte differentiation toward tumor-associated macrophage-like cells. Cancer Immunol. Immunother. 2010, 59:1097-1108.
79. Duluc D., et al. Tumor-associated leukemia inhibitory factor and IL-6 skew monocyte differentiation into tumor-associated macrophage-like cells. Blood 2007, 110:4319-4330.
80. Liu G., et al. SIRT1 limits the function and fate of myeloid-derived suppressor cells in tumors by orchestrating HIF-1α-dependent glycolysis. Cancer Res. 2014, 74:727-737.
81. Rigamonti N., et al. Modulators of arginine metabolism do not impact on peripheral T-cell tolerance and disease progression in a model of spontaneous prostate cancer. Clin. Cancer Res. 2011, 17:1012-1023.
82. Pearce E.J., Everts B. Dendritic cell metabolism. Nat. Rev. Immunol. 2015, 15:18-29.
83. DeNardo D.G., et al. CD4(+) T cells regulate pulmonary metastasis of mammary carcinomas by enhancing protumor properties of macrophages. Cancer Cell 2009, 16:91-102.
84. Biswas S.K., Mantovani A. Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm. Nat. Immunol. 2010, 11:889-896.
85. Modolell M., et al. Reciprocal regulation of the nitric oxide synthase/arginase balance in mouse bone marrow derived macrophages by Th1 and Th2 cytokines. Eur. J. Immunol. 1995, 25:1101-1104.
86. Locati M., et al. Analysis of the gene expression profile activated by the CC chemokine ligand 5/RANTES and by lipopolysaccharide in human monocytes. J. Immunol. 2002, 168:3557-3562.
87. Qian B-Z., Pollard J.W. Macrophage diversity enhances tumor progression and metastasis. Cell 2010, 141:39-51.
88. Biswas S.K. Metabolic reprogramming of immune cells in cancer progression. Immunity 2015, 43:435-449.
89. Colegio O.R., et al. Functional polarization of tumour-associated macrophages by tumour-derived lactic acid. Nature 2014, 513:559-563.
90. Shime H., et al. Tumor-secreted lactic acid promotes IL-23/IL-17 proinflammatory pathway. J. Immunol. 2008, 180:7175-7183.
91. Vats D., et al. Oxidative metabolism and PGC-1beta attenuate macrophage-mediated inflammation. Cell Metabolism. 2006, 4:13-24.
92. Jha Abhishek K., et al. Network integration of parallel metabolic and transcriptional data reveals metabolic modules that regulate macrophage polarization. Immunity 2015, 42:419-430.
93. Nasi A., et al. Dendritic cell reprogramming by endogenously produced lactic acid. J. Immunol. 2013, 191:3090-3099.
94. Tran Janco J.M., et al. Tumor-infiltrating dendritic cells in cancer pathogenesis. J. Immunol. 2015, 194:2985-2991.
95. Ahmadi M., et al. Prevention of Both direct and cross-priming of antitumor CD8+ T-cell responses following overproduction of prostaglandin E2 by tumor cells in vivo. Cancer Res. 2008, 68:7520-7529.
96. Herber D.L., et al. Lipid accumulation and dendritic cell dysfunction in cancer. Nat. Med. 2010, 16:880-886.
97. Cubillos-Ruiz Juan R., et al. ER stress sensor XBP1 controls anti-tumor immunity by disrupting dendritic cell homeostasis. Cell 2015, 161:1527-1538.
98. Hammami I., et al. Immunosuppressive activity enhances central carbon metabolism and bioenergetics in myeloid-derived suppressor cells in vitro models. BMC Cell Biol. 2012, 13:18.
99. Loberg R.D., et al. CCL2 as an important mediator of prostate cancer growth in vivo through the regulation of macrophage infiltration. Neoplasia 2007, 9:556-562.
100. Passaro C., et al. The oncolytic virus dl922-947 reduces IL-8/CXCL8 and MCP-1/CCL2 expression and impairs angiogenesis and macrophage infiltration in anaplastic thyroid carcinoma. Oncotarget 2015, Published online November 29, 2015. 10.18632/oncotarget.6430.
101. Azenshtein E., et al. The CC chemokine RANTES in breast carcinoma progression: regulation of expression and potential mechanisms of promalignant activity. Cancer Res. 2002, 62:1093-1102.
102. Soria G., et al. Concomitant expression of the chemokines RANTES and MCP-1 in human breast cancer: a basis for tumor-promoting interactions. Cytokine 2008, 44:191-200.
103. Yang L., et al. Abrogation of TGF beta signaling in mammary carcinomas recruits Gr-1+CD11b+ myeloid cells that promote metastasis. Cancer Cell 2008, 13:23-35.
104. Kowalczuk O., et al. CXCL5 as a potential novel prognostic factor in early stage non-small cell lung cancer: results of a study of expression levels of 23 genes. Tumour. Biol. 2014, 35:4619-4628.
105. Toh B., et al. Mesenchymal transition and dissemination of cancer cells is driven by myeloid-derived suppressor cells infiltrating the primary tumor. PLoS Biol. 2011, 9:e1001162.
106. Gijsbers K., et al. GCP-2/CXCL6 synergizes with other endothelial cell-derived chemokines in neutrophil mobilization and is associated with angiogenesis in gastrointestinal tumors. Exp. Cell Res. 2005, 303:331-342.
107. Wang N., et al. Neutrophils infiltration in the tongue squamous cell carcinoma and its correlation with CEACAM1 expression on tumor cells. PLoS ONE 2014, 9:e89991.
108. Trellakis S., et al. Polymorphonuclear granulocytes in human head and neck cancer: enhanced inflammatory activity, modulation by cancer cells and expansion in advanced disease. Int. J. Cancer 2011, 129:2183-2193.
109. Eck M., et al. Pleiotropic effects of CXC chemokines in gastric carcinoma: differences in CXCL8 and CXCL1 expression between diffuse and intestinal types of gastric carcinoma. Clin. Exp. Immunol. 2003, 134:508-515.
110. Bellocq A., et al. Neutrophil alveolitis in bronchioloalveolar carcinoma: induction by tumor-derived interleukin-8 and relation to clinical outcome. Am. J. Pathol. 1998, 152:83-92.
111. OuYang L-Y., et al. Tumor-induced myeloid-derived suppressor cells promote tumor progression through oxidative metabolism in human colorectal cancer. J. Transl. Med. 2015, 13:47.